Boston Scientific Corporation $BSX Position Decreased by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC has reduced its stake in Boston Scientific Corporation by 33% in Q1, now holding 225,990 shares, which represents 2.7% of their total holdings.
• Boston Scientific reported Q2 earnings of $0.75 per share, exceeding the expectation of $0.72, and its revenue increased by 22.8% year-over-year to $5.06 billion.
• Several hedge funds, including GAMMA Investing LLC and Vanguard Group Inc., have significantly increased their investments in Boston Scientific during recent quarters, indicating strong institutional confidence in the company's stock.

Parkman Healthcare Partners LLC trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 33.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 225,990 shares of the medical equipment provider's stock after selling 111,364 shares during the quarter. Boston Scientific makes up 2.7% of Parkman Healthcare Partners LLC's holdings, making the stock its 10th biggest holding. Parkman Healthcare Partners LLC's holdings in Boston Scientific were worth $22,798,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. NS Partners Ltd increased its holdings in Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after purchasing an additional 5,704 shares in the last quarter. Bank Pictet & Cie Europe AG increased its holdings in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares in the last quarter. Oppenheimer & Co. Inc. increased its holdings in shares of Boston Scientific by 18.8% during the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after acquiring an additional 6,264 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Boston Scientific during the first quarter valued at approximately $8,234,000. Finally, Blue Trust Inc. increased its holdings in shares of Boston Scientific by 13.0% during the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after acquiring an additional 575 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on BSX. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $118.00 to $125.00 in a report on Monday. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Needham & Company LLC restated a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a report on Wednesday, May 28th. UBS Group boosted their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Finally, Leerink Partners assumed coverage on Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and a consensus price target of $117.79.

Boston Scientific Stock Performance

NYSE:BSX traded up $0.35 during trading on Tuesday, reaching $108.49. The company's stock had a trading volume of 829,943 shares, compared to its average volume of 7,423,388. The firm has a market cap of $160.76 billion, a price-to-earnings ratio of 64.58, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a 50 day moving average of $104.78 and a 200-day moving average of $102.18. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares of the company's stock, valued at $222,646.19. This represents a 58.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $18,659,923.46. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $18,397,457 over the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.